top of page
Browse by category
Search
Women more likely to be aware of and have good understanding of obesity drugs
Women are much more aware of and knowledgeable about the obesity drugs GLP-1/GIP receptor agonists (that include semaglutide and...
GLP-1ras show anti-cancer benefits beyond weight loss
First generation weight-loss medications like liraglutide and exenatide appear to show anti-cancer benefits beyond weight loss. Indeed,...
First-in-human study of once-daily SYNT-101 oral treatment for obesity that mimics metabolic effects of gastric bypass without surgery
A first-in-human study of an investigational once-daily oral treatment for obesity (SYNT-101) demonstrated positive preliminary data for...
Global survey reveals high disconnect between perceptions of obesity among patient and healthcare professionals
A survey of adults living with obesity and their physicians across seven countries reveals a high disconnect between their perceptions...
GLP-1s post-bariatric surgery offer additional cardiovascular benefits
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) may help to reduce the risk of heart attacks, strokes, and other major adverse...
13TH IFSO-EC Congress - Venice 14-16th May 2025
The 13th Congress of the IFSO European Chapter (EC), taking place from May 15–17, 2025, in the enchanting city of Venice, Italy, will...
Browse by tag
bottom of page